90%Confidence
0Views
FDASource
2026-03-23Date
Summary
Harbin Jixianglong's Semaglutide recall due to validation failures highlights significant quality control risks in the compounding pharmacy supply chain for weight loss drugs. This may create supply constraints for compounding pharmacies relying on this API source.
Actionable: Immediately verify Semaglutide API sourcing for compounding operations and secure alternative validated suppliers to ensure continuity.
AI Confidence: 90%
Data Points
firmHarbin Jixianglong Biotech Co., Ltd.
classificationClass II
statusOngoing
distributionNationwide within the United States
productSemaglutide, For Rx compounding use only, packaged in a) 1g, NDC 84385-106-01; b) 5g, NDC 84385-106-02; c) 10g, NDC 84385-106-06; d) 25g, NDC 84385-1
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now